Cargando…

From Nanoparticles to Cancer Nanomedicine: Old Problems with New Solutions

Anticancer nanomedicines have been studied over 30 years, but fewer than 10 formulations have been approved for clinical therapy today. Despite abundant options of anticancer drugs, it remains challenging to have agents specifically target cancer cells while reducing collateral toxicity to healthy t...

Descripción completa

Detalles Bibliográficos
Autores principales: Chiang, Chi-Ling, Cheng, Ming-Huei, Lin, Chih-Hsin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8308137/
https://www.ncbi.nlm.nih.gov/pubmed/34209111
http://dx.doi.org/10.3390/nano11071727
_version_ 1783728209405149184
author Chiang, Chi-Ling
Cheng, Ming-Huei
Lin, Chih-Hsin
author_facet Chiang, Chi-Ling
Cheng, Ming-Huei
Lin, Chih-Hsin
author_sort Chiang, Chi-Ling
collection PubMed
description Anticancer nanomedicines have been studied over 30 years, but fewer than 10 formulations have been approved for clinical therapy today. Despite abundant options of anticancer drugs, it remains challenging to have agents specifically target cancer cells while reducing collateral toxicity to healthy tissue. Nanocompartments that can be selective toward points deeply within malignant tissues are a promising concept, but the heterogeneity of tumor tissue, inefficiency of cargo loading and releasing, and low uniformity of manufacture required from preclinical to commercialization are major obstacles. Technological advances have been made in this field, creating engineered nanomaterials with improved uniformity, flexibility of cargo loading, diversity of surface modification, and less inducible immune responses. This review highlights the developmental process of approved nanomedicines and the opportunities for novel materials that combine insights of tumors and nanotechnology to develop a more effective nanomedicine for cancer patients.
format Online
Article
Text
id pubmed-8308137
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-83081372021-07-25 From Nanoparticles to Cancer Nanomedicine: Old Problems with New Solutions Chiang, Chi-Ling Cheng, Ming-Huei Lin, Chih-Hsin Nanomaterials (Basel) Review Anticancer nanomedicines have been studied over 30 years, but fewer than 10 formulations have been approved for clinical therapy today. Despite abundant options of anticancer drugs, it remains challenging to have agents specifically target cancer cells while reducing collateral toxicity to healthy tissue. Nanocompartments that can be selective toward points deeply within malignant tissues are a promising concept, but the heterogeneity of tumor tissue, inefficiency of cargo loading and releasing, and low uniformity of manufacture required from preclinical to commercialization are major obstacles. Technological advances have been made in this field, creating engineered nanomaterials with improved uniformity, flexibility of cargo loading, diversity of surface modification, and less inducible immune responses. This review highlights the developmental process of approved nanomedicines and the opportunities for novel materials that combine insights of tumors and nanotechnology to develop a more effective nanomedicine for cancer patients. MDPI 2021-06-30 /pmc/articles/PMC8308137/ /pubmed/34209111 http://dx.doi.org/10.3390/nano11071727 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Chiang, Chi-Ling
Cheng, Ming-Huei
Lin, Chih-Hsin
From Nanoparticles to Cancer Nanomedicine: Old Problems with New Solutions
title From Nanoparticles to Cancer Nanomedicine: Old Problems with New Solutions
title_full From Nanoparticles to Cancer Nanomedicine: Old Problems with New Solutions
title_fullStr From Nanoparticles to Cancer Nanomedicine: Old Problems with New Solutions
title_full_unstemmed From Nanoparticles to Cancer Nanomedicine: Old Problems with New Solutions
title_short From Nanoparticles to Cancer Nanomedicine: Old Problems with New Solutions
title_sort from nanoparticles to cancer nanomedicine: old problems with new solutions
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8308137/
https://www.ncbi.nlm.nih.gov/pubmed/34209111
http://dx.doi.org/10.3390/nano11071727
work_keys_str_mv AT chiangchiling fromnanoparticlestocancernanomedicineoldproblemswithnewsolutions
AT chengminghuei fromnanoparticlestocancernanomedicineoldproblemswithnewsolutions
AT linchihhsin fromnanoparticlestocancernanomedicineoldproblemswithnewsolutions